464 related articles for article (PubMed ID: 21145866)
1. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.
Bremer CM; Sominskaya I; Skrastina D; Pumpens P; El Wahed AA; Beutling U; Frank R; Fritz HJ; Hunsmann G; Gerlich WH; Glebe D
J Hepatol; 2011 Jul; 55(1):29-37. PubMed ID: 21145866
[TBL] [Abstract][Full Text] [Related]
2. Fine mapping of virus-neutralizing epitopes on hepatitis B virus PreS1.
Maeng CY; Ryu CJ; Gripon P; Guguen-Guillouzo C; Hong HJ
Virology; 2000 Apr; 270(1):9-16. PubMed ID: 10772975
[TBL] [Abstract][Full Text] [Related]
3. Properties of modified hepatitis B virus surface antigen particles carrying preS epitopes.
Prange R; Werr M; Birkner M; Hilfrich R; Streeck RE
J Gen Virol; 1995 Sep; 76 ( Pt 9)():2131-40. PubMed ID: 7561750
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies.
Niedre-Otomere B; Bogdanova A; Skrastina D; Zajakina A; Bruvere R; Ose V; Gerlich WH; Garoff H; Pumpens P; Glebe D; Kozlovska T
J Viral Hepat; 2012 Sep; 19(9):664-73. PubMed ID: 22863271
[TBL] [Abstract][Full Text] [Related]
5. Identification of the immunogenic domains in HBsAg preS1 region using overlapping preS1 fragment fusion proteins.
Hu WG; Wei J; Xia HC; Yang XX; Li F; Li GD; Wang Y; Zhang ZC
World J Gastroenterol; 2005 Apr; 11(14):2088-94. PubMed ID: 15810073
[TBL] [Abstract][Full Text] [Related]
6. Behavior of a short preS1 epitope on the surface of hepatitis B core particles.
Borisova G; Borschukova O; Skrastina D; Dislers A; Ose V; Pumpens P; Grens E
Biol Chem; 1999 Mar; 380(3):315-24. PubMed ID: 10223334
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice.
Yue Q; Hu X; Yin W; Xu X; Wei S; Lei Y; Lü X; Yang J; Su M; Xu Z; Hao X
J Virol Methods; 2007 Apr; 141(1):41-8. PubMed ID: 17197041
[TBL] [Abstract][Full Text] [Related]
8. Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype.
Sobotta D; Sominskaya I; Jansons J; Meisel H; Schmitt S; Heermann KH; Kaluza G; Pumpens P; Gerlich WH
J Gen Virol; 2000 Feb; 81(Pt 2):369-78. PubMed ID: 10644835
[TBL] [Abstract][Full Text] [Related]
9. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees.
Hong HJ; Ryu CJ; Hur H; Kim S; Oh HK; Oh MS; Park SY
Virology; 2004 Jan; 318(1):134-41. PubMed ID: 14972542
[TBL] [Abstract][Full Text] [Related]
10. High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers.
Skrastina D; Bulavaite A; Sominskaya I; Kovalevska L; Ose V; Priede D; Pumpens P; Sasnauskas K
Vaccine; 2008 Apr; 26(16):1972-81. PubMed ID: 18343539
[TBL] [Abstract][Full Text] [Related]
11. A C-terminal PreS1 sequence is sufficient to retain hepatitis B virus L protein in 293 cells.
Gallina A; Gazina E; Milanesi G
Virology; 1995 Oct; 213(1):57-69. PubMed ID: 7483279
[TBL] [Abstract][Full Text] [Related]
12. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus.
Yang HJ; Chen M; Cheng T; He SZ; Li SW; Guan BQ; Zhu ZH; Gu Y; Zhang J; Xia NS
World J Gastroenterol; 2005 Jan; 11(4):492-7. PubMed ID: 15641132
[TBL] [Abstract][Full Text] [Related]
13. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes.
Glebe D; Urban S; Knoop EV; Cag N; Krass P; Grün S; Bulavaite A; Sasnauskas K; Gerlich WH
Gastroenterology; 2005 Jul; 129(1):234-45. PubMed ID: 16012950
[TBL] [Abstract][Full Text] [Related]
14. Attachment sites and neutralising epitopes of hepatitis B virus.
Glebe D
Minerva Gastroenterol Dietol; 2006 Mar; 52(1):3-21. PubMed ID: 16554703
[TBL] [Abstract][Full Text] [Related]
15. PreS deletion mutations of hepatitis B virus in chronically infected patients with simultaneous seropositivity for hepatitis-B surface antigen and anti-HBS antibodies.
Huang X; Qin Y; Zhang P; Tang G; Shi Q; Xu J; Qi F; Shen Q
J Med Virol; 2010 Jan; 82(1):23-31. PubMed ID: 19950231
[TBL] [Abstract][Full Text] [Related]
16. Applications of human hepatitis B virus preS domain in bio- and nanotechnology.
Toita R; Kawano T; Kang JH; Murata M
World J Gastroenterol; 2015 Jun; 21(24):7400-11. PubMed ID: 26139986
[TBL] [Abstract][Full Text] [Related]
17. Generation and Characterization of a Neutralizing Human Monoclonal Antibody to Hepatitis B Virus PreS1 from a Phage-Displayed Human Synthetic Fab Library.
Jo G; Jeong MS; Wi J; Kim DH; Kim S; Kim D; Yoon JY; Chae H; Kim KH; Hong HJ
J Microbiol Biotechnol; 2018 Aug; 28(8):1376-1383. PubMed ID: 30301315
[TBL] [Abstract][Full Text] [Related]
18. [Immunological and virological efficacy against HBV chronic infection of the therapeutic vaccine composed of HBV core plus PreS1 in HBV transgenic mice].
Li MZ; Chen XC; Zhou BP; Le XH; Xu LM; Wang HS
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):277-9. PubMed ID: 15340577
[TBL] [Abstract][Full Text] [Related]
19. A monoclonal antibody specific to the non-epitope region of hepatitis B virus preS1 contributes to more effective HBV detection.
Zhang Z; Li X; Yi W; Li S; Hu C; Chen A
Clin Biochem; 2013 Aug; 46(12):1105-1110. PubMed ID: 23608352
[TBL] [Abstract][Full Text] [Related]
20. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
